Literature DB >> 15247216

An exonic splicing enhancer offsets the atypical GU-rich 3' splice site of human apolipoprotein A-II exon 3.

Pablo Arrisi-Mercado1, Maurizio Romano, Andres F Muro, Francisco E Baralle.   

Abstract

Human apolipoprotein A-II (apoA-II) intron 2/exon 3 junction shows a peculiar tract of alternating pyrimidines and purines (GU tract) that makes the acceptor site deviate significantly from the consensus. However, apoA-II exon 3 is constitutively included in mRNA. We have studied this unusual exon definition by creating a construct with the genomic fragment encompassing the whole gene from apoA-II and its regulatory regions. Transient transfections in Hep3B cells have shown that deletion or replacement of the GU repeats at the 3' splice site resulted in a decrease of apoA-II exon 3 inclusion, indicating a possible role of the GU tract in splicing. However, a 3' splice site composed of the GU tract in heterologous context, such as the extra domain A of human fibronectin or cystic fibrosis transmembrane conductance regulator exon 9, resulted in total skipping of the exons. Next, we identified the exonic cis-acting elements that may affect the splicing efficiency of apoA-II exon 3 and found that the region spanning from nucleotide 87 to 113 of human apoA-II exon 3 is essential for its inclusion in the mRNA. Overlapping deletions and point mutations (between nucleotides 91 and 102) precisely defined an exonic splicing enhancer (ESEwt). UV cross-linking assays followed by immunoprecipitation with anti-SR protein monoclonal antibodies showed that ESEwt, but not mutated ESE RNA, was able to bind both alternative splicing factor/splicing factor 2 and SC35. Furthermore, overexpression of both splicing factors enhanced exon 3 inclusion. These results show that this protein-ESE interaction is able to promote the incorporation of exon 3 in mRNA and suggest that they can rescue the splicing despite the noncanonical 3' splice site.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247216     DOI: 10.1074/jbc.M405566200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well.

Authors:  Gerrit M Daubner; Antoine Cléry; Sandrine Jayne; James Stevenin; Frédéric H-T Allain
Journal:  EMBO J       Date:  2011-10-14       Impact factor: 11.598

2.  Identification of splicing silencers and enhancers in sense Alus: a role for pseudoacceptors in splice site repression.

Authors:  Haixin Lei; Igor Vorechovsky
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

Review 3.  RNA processing defects associated with diseases of the motor neuron.

Authors:  Stephen J Kolb; Scott Sutton; Daniel R Schoenberg
Journal:  Muscle Nerve       Date:  2010-01       Impact factor: 3.217

4.  Evolutionarily conserved heterogeneous nuclear ribonucleoprotein (hnRNP) A/B proteins functionally interact with human and Drosophila TAR DNA-binding protein 43 (TDP-43).

Authors:  Maurizio Romano; Emanuele Buratti; Giulia Romano; Raffaella Klima; Lisa Del Bel Belluz; Cristiana Stuani; Francisco Baralle; Fabian Feiguin
Journal:  J Biol Chem       Date:  2014-02-03       Impact factor: 5.157

5.  Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.

Authors:  Jian Zhang; Yen K Lieu; Abdullah M Ali; Alex Penson; Kathryn S Reggio; Raul Rabadan; Azra Raza; Siddhartha Mukherjee; James L Manley
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

6.  Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene.

Authors:  Pablo Arrisi Mercado; Youhna M Ayala; Maurizio Romano; Emanuele Buratti; Francisco E Baralle
Journal:  Nucleic Acids Res       Date:  2005-10-27       Impact factor: 16.971

7.  Pressure-overload cardiac hypertrophy is associated with distinct alternative splicing due to altered expression of splicing factors.

Authors:  Taeyong Kim; Jin Ock Kim; Jae Gyun Oh; Seong-Eui Hong; Do Han Kim
Journal:  Mol Cells       Date:  2014-01-27       Impact factor: 5.034

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.